These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 35757417)

  • 21. Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome.
    Nugent D; Vandekerckhove P; Hughes E; Arnot M; Lilford R
    Cochrane Database Syst Rev; 2000; (4):CD000410. PubMed ID: 11034687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dynamics of serum anti-Mullerian-hormone levels during controlled ovarian hyperstimulation with GnRH-antagonist short protocol in polycystic ovary syndrome and low responders.
    Weintraub A; Margalioth EJ; Chetrit AB; Gal M; Goldberg D; Alerhand S; Eldar-Geva T
    Eur J Obstet Gynecol Reprod Biol; 2014 May; 176():163-7. PubMed ID: 24630573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of the efficiency between in-vitro maturation and in-vitro fertilization after early follicular phase GnRH agonist down-regulation in infertile women with polycystic ovary syndrome].
    Zhu RR; Xiao SQ; Zhao JZ; Lin J; Wang PY; Jin CC; Jin WM
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):833-7. PubMed ID: 24444560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
    Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels.
    Manzanares MA; Gómez-Palomares JL; Ricciarelli E; Hernández ER
    Fertil Steril; 2010 Mar; 93(4):1215-9. PubMed ID: 19200978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential response of AMH to GnRH agonist among individuals: the effect on ovarian stimulation outcomes.
    Cai J; Liu L; Zheng J; Zhang L; Jiang X; Li P; Sha A; Ren J
    J Assist Reprod Genet; 2018 Mar; 35(3):467-473. PubMed ID: 29264688
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An AMH-based FSH dosing algorithm for OHSS risk reduction in first cycle antagonist protocol for IVF/ICSI.
    Sopa N; Larsen EC; Westring Hvidman H; Andersen AN
    Eur J Obstet Gynecol Reprod Biol; 2019 Jun; 237():42-47. PubMed ID: 31009858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The addition of anti-Müllerian hormone in an algorithm for individualized hormone dosage did not improve the prediction of ovarian response-a randomized, controlled trial.
    Magnusson Å; Nilsson L; Oleröd G; Thurin-Kjellberg A; Bergh C
    Hum Reprod; 2017 Apr; 32(4):811-819. PubMed ID: 28175316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myoinositol
    Rajasekaran K; Malhotra N; Mahey R; Khadgawat R; Kalaivani M
    Gynecol Endocrinol; 2022 Feb; 38(2):140-147. PubMed ID: 34590929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laparoscopic ovarian drilling versus GnRH antagonist combined with cabergoline as a prophylaxis against the re-development of ovarian hyperstimulation syndrome.
    Seyam E; Hefzy E
    Gynecol Endocrinol; 2018 Jul; 34(7):616-622. PubMed ID: 29334275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the proportion of dominant follicles in patients with polycystic ovary syndrome undergoing in vitro fertilization-embryo transfer.
    Lin HY; Li Y; Wang WJ; Qiu Q; Zhang QX; Li Y
    Chin Med J (Engl); 2019 Jun; 132(12):1448-1453. PubMed ID: 31205103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. WITHDRAWN: Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome.
    Hughes E; Collins J; Vandekerckhove P
    Cochrane Database Syst Rev; 1996 Apr; (1):CD000087. PubMed ID: 17636586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of different gonadotropin preparations in GnRH antagonist protocol for patients with polycystic ovary syndrome during IVF/ICSI: a retrospective cohort study.
    Hu Z; Zeng R; Gao R; Chen M; Liu X; Zhang Q; Qin L; Zeng X
    Front Endocrinol (Lausanne); 2024; 15():1309993. PubMed ID: 38410698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach.
    Fernández-Sánchez M; Fatemi H; García-Velasco JA; Heiser PW; Daftary GS; Mannaerts B
    Gynecol Endocrinol; 2023 Dec; 39(1):2205952. PubMed ID: 37156263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of hyperandrogenism on pregnancy outcomes in women with polycystic ovary syndrome undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer].
    Jiang LL; Pan P; Jiao XD; Qiu Q; Li Y; Zhang QX
    Zhonghua Yi Xue Za Zhi; 2023 Apr; 103(14):1042-1048. PubMed ID: 37032154
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.